Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
Profitability Metrics
Gross Margin
89.00%
Operating Margin
4.93%
Net Margin
-14.09%
Efficiency Metrics
Revenue per Expense Ratio
1.05
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
49.93%
Income Tax Rate
0.00%
EPS
-1.3600000000
Balance Sheet Analysis
Current Ratio
0.11
Cash Ratio
0.01
Working Capital
$-235.73M
Debt to Equity
1.78
Debt to Assets
48.48%
Equity Ratio
27.21%
Cash Flow Analysis
Operating Cash Flow Ratio
35.32%
Free Cash Flow Ratio
25.20%
CapEx to Revenue
10.12%
Dividends Paid
$11.84M
Stock Buybacks
$1.13M
Total Shareholder Returns
$12.97M
Cash Position Change
-63.65%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 5.95%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
1.65%
Net Income
66.82%
EPS
48.87%
Operating Income
-81.53%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
74.43%
Operating Cash Flow
-0.42%
Free Cash Flow
63.39%
Balance Sheet Health
Assets
16.42%
Debt
43.12%
Book Value per Share
-7.49%
Inventory
121.34%
Shareholder Returns
Dividends per Share
5.95%
Shares Outstanding
0.96%
Long Term Trends
3Y Revenue/Share
27.79%
5Y Revenue/Share
100.00%
3Y Dividend/Share
149.92%
5Y Dividend/Share
100.00%